Publication:
Repositioning of anti-inflammatory drugs for the treatment of cervical cancer sub-types

Simple item page
dc.contributor.authorTURANLI, BESTE
dc.contributor.authorARĞA, KAZIM YALÇIN
dc.contributor.authorsKori M., ARĞA K. Y., Mardinoglu A., TURANLI B.
dc.date.accessioned2023-07-25T10:20:20Z
dc.date.available2023-07-25T10:20:20Z
dc.date.issued2022-06-01
dc.description.abstractCervical cancer is the fourth most commonly diagnosed cancer worldwide and, in almost all cases is caused by infection with highly oncogenic Human Papillomaviruses (HPVs). On the other hand, inflammation is one of the hallmarks of cancer research. Here, we focused on inflammatory proteins that classify cervical cancer patients by considering individual differences between cancer patients in contrast to conventional treatments. We repurposed anti-inflammatory drugs for therapy of HPV-16 and HPV-18 infected groups, separately. In this study, we employed systems biology approaches to unveil the diagnostic and treatment options from a precision medicine perspective by delineating differential inflammation-associated biomarkers associated with carcinogenesis for both subtypes. We performed a meta-analysis of cervical cancer-associated transcriptomic datasets considering subtype differences of samples and identified the differentially expressed genes (DEGs). Using gene signature reversal on HPV-16 and HPV-18, we performed both signature- and network-based drug reversal to identify anti-inflammatory drug candidates against inflammation-associated nodes. The anti-inflammatory drug candidates were evaluated using molecular docking to determine the potential of physical interactions between the anti-inflammatory drug and inflammation-associated nodes as drug targets. We proposed 4 novels anti-inflammatory drugs (AS-601245, betamethasone, narciclasin, and methylprednisolone) for the treatment of HPV-16, 3 novel drugs for the treatment of HPV-18 (daphnetin, phenylbutazone, and tiaprofenoic acid), and 5 novel drugs (aldosterone, BMS-345541, etodolac, hydrocortisone, and prednisolone) for the treatment of both subtypes. We proposed anti-inflammatory drug candidates that have the potential to be therapeutic agents for the prevention and/or treatment of cervical cancer.
dc.identifier.citationKori M., ARĞA K. Y., Mardinoglu A., TURANLI B., "Repositioning of Anti-Inflammatory Drugs for the Treatment of Cervical Cancer Sub-Types", FRONTIERS IN PHARMACOLOGY, cilt.13, 2022
dc.identifier.doi10.3389/fphar.2022.884548
dc.identifier.issn1663-9812
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/994cf88a-d963-462b-a2fc-93ac070a84e0/file
dc.identifier.urihttps://hdl.handle.net/11424/291574
dc.identifier.volume13
dc.language.isoeng
dc.relation.ispartofFRONTIERS IN PHARMACOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTemel Eczacılık Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectBasic Pharmaceutics Sciences
dc.subjectHealth Sciences
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectNatural Sciences
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectLife Sciences (LIFE)
dc.subjectFarmakoloji
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji (tıbbi)
dc.subjectİlaç Rehberleri
dc.subjectPharmacy
dc.subjectPharmacology
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology (medical)
dc.subjectDrug Guides
dc.subjectinflammation
dc.subjectdrug repurposing
dc.subjectanti-inflammatory drugs
dc.subjectcervical cancer
dc.subjecthuman papillomavirus 16
dc.subjecthuman papillomavirus 18
dc.subjectGENE-EXPRESSION
dc.subjectINFLAMMATION
dc.subjectAPOPTOSIS
dc.subjectCELLS
dc.subjectASPIRIN
dc.subjectGROWTH
dc.subjectTOOL
dc.subjectinflammation
dc.subjectdrug repurposing
dc.subjectanti-inflammatory drugs
dc.subjectcervical cancer
dc.subjecthuman papillomavirus 16
dc.subjecthuman papillomavirus 18
dc.titleRepositioning of anti-inflammatory drugs for the treatment of cervical cancer sub-types
dc.typearticle
dspace.entity.typePublication
local.avesis.id994cf88a-d963-462b-a2fc-93ac070a84e0
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication3e8c4f64-93ae-4b42-953c-35c8b07586b3
relation.isAuthorOfPublication3582c2d4-7fbb-4db7-8e90-75613782b894
relation.isAuthorOfPublication.latestForDiscovery3e8c4f64-93ae-4b42-953c-35c8b07586b3

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
34.pdf
Size:
3.64 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs